Jazz (JAZZ) delivered earnings and revenue surprises of +35.91% and +9.97%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals (NASDAQ: JAZZ) is currently trading at approximately $110, having decreased by 11% year-to-date, even after a significant positive development with the conditional European ...

Jazz Pharmaceuticals JAZZ reported second-quarter 2025 adjusted loss of $8.25 per share, wider than the Zacks Consensus Estimate of a loss of $6.12. This downtick was primarily due to a one-time ...

Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) announced in Q1 CY2026, with sales up 19.1% year on year to $1.07 ...

Share price of JAZZ Pharmaceuticals JAZZ hit $102.82 on Tuesday, close to its 52-week low of $99.06. This decline is attributable to the significant downturn in the broader biotech/drug sector due to ...

JAZZ Pharmaceuticals JAZZ is not your typical cannabis stock involved in cultivation, processing, or sales of marijuana products. Instead, this commercial-stage biotech is the only one to market an ...

Ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Zymeworks Inc. (NASDAQ: ZYME) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro. Zymework, along with its partners, ...